Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population
Even in a memory clinic with a good infrastructure and sufficient facilities for dementia diagnostics, most patients do not meet the eligibility criteria for treatment with lecanemab.
Authors
- Josef Marksteiner
- Michaela Defrancesco (ORCID: https://orcid.org/0000-0001-9613-9485)
- Elke R. Gizewski (ORCID: https://orcid.org/0000-0001-6859-8377)
- Alex Hofer (ORCID: https://orcid.org/0000-0002-5834-4258)
- Alexander Kroiss
- Malik Galijašević (ORCID: https://orcid.org/0000-0001-6577-0784)
- Irene Johanna Virgolini (ORCID: https://orcid.org/0000-0001-7097-6170)
- Stephanie Mangesius (ORCID: https://orcid.org/0000-0001-5790-2724)
- Burak Doganyigit
- J Jehle
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Tirol Kliniken (AT)
Publication Details
- Journal
- BJPsych Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1192/bjo.2024.747
- Citations
- 11
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 4.24
Funders
- Medizinische Universität Innsbruck
- Universität Innsbruck